These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17674545)

  • 1. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
    Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
    Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
    Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
    Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
    Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F
    Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate.
    Chiang KC; Chen TW; Yeh CN; Liu FY; Lee HL; Jan YY
    World J Gastroenterol; 2006 Apr; 12(13):2060-4. PubMed ID: 16610057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
    Kasper B; Kallinowski B; Herrmann T; Lehnert T; Mechtersheimer G; Geer T; Ho AD; Egerer G
    Dig Dis; 2006; 24(1-2):207-11. PubMed ID: 16699280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
    Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
    Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.